1446090-79-4

Basic information

• Product Name: 5-((1-(6-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-5-yl)oxy)-3,4-dihydro-1,8-naphthyridin-2(1H)-one
• Synonyms: 5-((1-(6-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-5-yl)oxy)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;EOS-60483
• CAS NO: 1446090-79-4
• Molecular Formula: C25H17F3N4O3
• Molecular Weight: 478.4226896
• Mol File: 1446090-79-4.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 651.9±65.0 °C(Predicted)
• Appearance: /
• Density: 1.72±0.1 g/cm3(Predicted)
• PKA: 10.16±0.10(Predicted)
• CAS DataBase Reference: 5-((1-(6-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-5-yl)oxy)-3,4-dihydro-1,8-naphthyridin-2(1H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5-((1-(6-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-5-yl)oxy)-3,4-dihydro-1,8-naphthyridin-2(1H)-one(1446090-79-4)
• EPA Substance Registry System: 5-((1-(6-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-5-yl)oxy)-3,4-dihydro-1,8-naphthyridin-2(1H)-one(1446090-79-4)

Safety Data

• Hazardous Substances Data: 1446090-79-4(Hazardous Substances Data)

Usage

Uses

Lifirafenib it is quinoline derivative used for combination treatment of small cell lung cancer.

Upstream product

• 13391-28-1 5-methoxybenzofuran 
• 1446091-46-8 (1S,1aS,6bR)-5-((7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy)-1a,6b-dihydro-1H-cyclopropane[b]benzofuran-1-carboxylic acid 
• 1446091-45-7 (1S,1aS,6bR)-5-((7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy)-1a,6b-dihydro-1H-cyclopropane[b]benzofuran-1-carboxylic acid ethyl ester 
• 1446091-43-5 (1S,1aS,6bR)-5-hydroxy-1a,6b-dihydro-1H-cyclopropane[b]benzofuran-1-carboxylic acid ethyl ester 
• 1446091-44-6 (1S,1aS,6bR)-5-((tert-butyldimethylsilyl)oxy)-1a,6b-dihydro-1H-cyclopropane[b]benzofuran-1-carboxylic acid ethyl ester 
• 368-71-8 4-(trifluoromethyl)-1,2-phenylenediamine 
• 13196-10-6 benzofuran-5-ol 
• 1237535-78-2 5-fluoro-3,4-dihydro-1,8-naphthyridine-2(1H)-one 

Relevant articles and documents

COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER

Disclosed herein is a pharmaceutical combination for use in the prevention, delay of progression or treatment of cancer, wherein the pharmaceutical combination exhibits a synergistic efficacy. The pharmaceutical combination comprises a humanized antagonist monoclonal antibody against PD- and a RAF inhibitor. Also disclosed herein is a combination for use in the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject a therapeutically effective amount of a humanized antagonist monoclonal antibody against PD-1 and a therapeutically effective amount of a RAF inhibitor.

MALEATE SALTS OF A B-RAF KINASE INHIBITOR, CRYSTALLINE FORMS, METHODS OF PREPARATION, AND USES THEREFORE

The invention relates to 5- ( ( (1R, 1aS, 6bR) -1- (6- (trifluoromethyl) -1H-benzo [d] imidazol-2-yl) -1a,6b-dihydro-1H-cyclopropa [b] benzofuran-5-yl) oxy) -3, 4-dihydro-1, 8-naphthyridin-2 (1H) -one (Compound 1) maleate salts, in particular the sesqui-maleate salt and its crystalline forms, methods of preparation, pharmaceutical compositions, and therapeutic uses for treatment of diseases or disorders mediated by BRAF or other kinases.

CONDENSED TRICYCLIC COMPOUNDS AS Raf KINASE INHIBITORS

PROBLEM TO BE SOLVED: To provide specific tricyclic compounds that can be useful for inhibiting Raf kinase and for treating disorders mediated by Raf kinase. SOLUTION: A compound is represented by the general formula 1 in the figure. (Q is C or N; W is C or N; X is CH2 or O; Y is NR12, O or S; Z is O, S, NR13, CO, SO, SO2 or CR13R14; R1 to R6 are each independently hydrogen, halogen, haloalkyl, alkyl or the like.) SELECTED DRAWING: None COPYRIGHT: (C)2017,JPO&INPIT